CVS Health Corp vs Northrop Grumman Corporation — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.29B), while Northrop Grumman Corporation trades at $484.49 (market cap $67.26B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Northrop Grumman Corporation for 81 Days on average.
| CVS | NOC | |
|---|---|---|
Market Cap | $112.29B | $67.26B |
Volume | 7,763,676 | 711,592 |
Sector | Health | Industrials |
52-Week High | $110.60 | $768.02 |
52-Week Low | $70.08 | $473.46 |
Typical Hold Time | 83 Days | 81 Days |
Enterprise Value | $174.64B | $81.24B |
Dividend Yield | 3.03% | 2.09% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
Northrop Grumman (NOC) trades at $484.48, up 0.28% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $7.68 exceeding expectations by 12.6%. Recent news highlights the loss of a $20B Navy fighter contract to Boeing, creating near-term headwinds. Technical indicators show oversold conditions with RSI at 16.17, while the stock trades below key resistance at $484.
NOC presents a compelling value opportunity with a 15.05 P/E ratio and 26.96% ROE, supported by a 54% analyst buy rating and $615.75 price target. Risks include competitive contract losses and defense budget uncertainties, but the company's $104.7B backlog and dividend growth provide stability. The current technical weakness may offer entry points for long-term investors seeking defense exposure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →